SCHEMBL19783280

SCHEMBL19783280

Cc1cc(Br)c2ncc(COc3ccccc3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYSLTR1 Q9Y271 4/20 0.46
CYSLTR2 Q9NS75 2/20 0.46
KCNH2 Q12809 1/20 0.44
FFAR1 O14842 2/20 0.43
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
NOS1 P29475 2/20 0.39
GPBAR1 Q8TDU6 4/20 0.38
MAPT P10636 1/20 0.38
IDH1 O75874 1/20 0.37
F2RL3 Q96RI0 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 1/20 0.37
GRM5 P41594 1/20 0.37
NOS3 P29474 1/20 0.36
NOS2 P35228 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19776270 0.81 F2RL3 (0.38) KDM4EALDH1A1HPGDMAPTF2RL3
SCHEMBL19783152 0.79 KDM4E (0.32) KDM4ENOS1MAPTF2RL3LMNA
SCHEMBL19783200 0.78 NOS3 (0.37) KDM4EMAPTF2RL3LMNANOS3
SCHEMBL19783582 0.77 CYSLTR1 (0.42) CYSLTR1CYSLTR2KCNH2FFAR1KDM4E
SCHEMBL19775902 0.77 NQO2 (0.32) F2RL3
SCHEMBL19776222 0.76 F2RL3 (0.33) F2RL3
SCHEMBL29481808 0.73 PDGFRB (0.50) MAPTNPC1RAB9AGRM5
SCHEMBL19776515 0.73 PDGFRB (0.50) MAPTNPC1RAB9AGRM5
SCHEMBL19783264 0.72 F2RL3 (0.62) F2RL3
SCHEMBL29481835 0.71 CCR1 (0.36) KDM4EHPGDF2RL3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12060347-B2 Bicyclic heteroaryl substituted compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-13 US disclosed
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
EP-3484878-B1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-08-19 EP disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
CN-109689647-A The compound that bicyclic heteroaryl replaces 百时美施贵宝公司 2019-04-26 CN disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060347-B2 Bicyclic heteroaryl substituted compounds F2, F2RL3, F12 CYSLTR1 1837/4885CYSLTR2 1967/4885KCNH2 3719/4885
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CYSLTR1 2196/4885CYSLTR2 2133/4885KCNH2 3616/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CYSLTR1 1837/4885CYSLTR2 1967/4885KCNH2 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.